Premium
THE COMBINATION OF VENETOCLAX AND IBRUTINIB IS EFFECTIVE IN RELAPSED/REFRACTORY T‐PROLYMPHOCYTIC LEUKEMIA AND INFLUENCES BCL‐2‐FAMILY MEMBER DEPENDENCIES
Author(s) -
Kornauth C.F.,
Herbaux C.,
Boidol B.,
Guillemette C.,
Mayerhöfer M.E.,
Jäger U.,
Kubicek S.,
Davids M.S.,
Staber P.B.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.161_2631
Subject(s) - venetoclax , ibrutinib , prolymphocytic leukemia , idelalisib , medicine , gemcitabine , oncology , cancer research , leukemia , pharmacology , chemotherapy , chronic lymphocytic leukemia
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom